140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

Adil Daud(University of California, San Francisco), A. Ribas, Hassane M. Zarour(University of Pittsburgh), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), X. Li, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), W. Hwu, Marisa Dolled‐Filhart(Fox Chase Cancer Center), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), K. Gerigich, Caroline Robert(Institut Gustave Roussy), Tara C. Gangadhar(University of Pennsylvania), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), P Kang

European Journal of Cancer

November 1, 2014

Cited by 6

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.9k

|New England Journal of Medicine|2014|5.3k

Related Papers